Avdoralimab structure
|
Common Name | Avdoralimab | ||
---|---|---|---|---|
CAS Number | 2226393-85-5 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of AvdoralimabAvdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research[1]. |
Name | Avdoralimab |
---|
Description | Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research[1]. |
---|---|
Related Catalog | |
In Vitro | Avdoralimab (IPH 5401) 选择性阻断人骨髓细胞中的 C5a-C5aR1 相互作用及其下游信号传导。在体外,用 Avdoralimab (10-30 μg/mL) 阻断 C5aR1 可抑制 C5a 诱导的中性粒细胞活化。Avdoralimab 阻断由非常高浓度的 C5a 诱导的嗜中性粒细胞活化。Avdoralimab 还在体外抑制 C5a 诱导的中性粒细胞迁移[1]。 |
In Vivo | 在敲入人类 C5aR1 的小鼠(HuC5aR1 KI 小鼠)中,Avdoralimab 阻断嗜中性粒细胞和单核细胞的浸润,阻止白蛋白在支气管肺泡灌洗液 (BALF) 中的释放,并限制 C5a 诱导的急性肺损伤 (ALI) 组织病理学特征[1]。 |
References |
No Any Chemical & Physical Properties |